Abstract
Serum tumor markers may be requested inappropriately by clinicians. In this retrospective study, we aimed to investigate the appropriateness of TM requests in our hospital. Patients in the study were identified from the TM requests for 3 months between June–August 2004, using the laboratory database. A total of 2249 patients (1351 men, 898 women) were included in the study and there were 6570 TM requests. The number of requests were 1050 (16%) for Carbohydrate Antigen 19-9, 993 (15.1%) for Cancer Antigen 125, 941 (14.3%) for Prostate Specific Antigen, 921 (14%) for free PSA, 925 (14.1%) for Cancer Antigen 15-3, 788 (12%) for Alphafetoprotein, 730 (11.1%) for Carcinoembryonic Antigen and 222 (3.4%) for AFP/Human Chorionic Gonadotrophin. Our findings support the idea that for the evidence-based use of TM requests the education of clinical staff is required. Clear clinical guidelines including recommendations about the appropriate use of TM can be useful for this education process. Careful audit studies are also useful to determine the impact of these guidelines on the practice of evidence-based laboratory medicine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865–78.
Ruoslahti E, Salaspuro M, Pihko H, Anderson L, Seppala M. Serum α-fetoprotein: diagnostic significance in liver disease. Br Med J 1974; 8: 527–9.
Fletcher RH. Carcinoembrionic antigen. Ann Intern Med 1986; 104: 66–78.
Thomas P, Zamcheck N. Role of liver in clearance and excretion of circulating carcinoembriogenic antigen (CEA). Dig Dis Sci 1983; 28: 216–24.
Jacops IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, et al. Screening for ovarian cancer; a pilot randomised controlled trial. Lancet 1999; 353: 1207–10.
Gallup DG, Talledo E. Management of the adnexial mass in the 1990s. South Med J 1997; 90: 972–81.
Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990; 85: 350–5.
Mazumdar M, Bajorin D, Bacik J, Higgins G, Motzer RJ, Bost GI. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 2001; 19: 2534–41.
Carter HB, Pearson JD, Metter EJ, Brant L, Chan DW, Andrea R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 257: 2215–20.
Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clin Chem 2002; 48: 1151–9.
European Society for Medical Oncology. ESMO minimum clinical recommendations for diagnosis, adjuvant treatment and follow-up of colon cancer. Ann Oncol 2001; 12: 1053–4.
McDonnell M. An audit of tumor marker requests in Northern Ireland: Ann Clin Biochem 2004; 41: 378–84.
Duffy MJ. CA 19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem 1998; 35: 364–70
Klaptor R, Aranson AC, Duffy MJ, Hansson LO, Khalifa R, Lamerz R, et al. Tumor markers in gastrointestinal cancers: EGTM recommendations. Anticancer Res 1999; 19: 2807–10.
Rustin GJ. The clinical value of tumor markers in the management of ovarian cancer. Ann Clin Biochem 1996; 33:284–9.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yilmaz, G., Yilmaz, F.M., Senes, M. et al. Tumor marker requests in a general teaching Turkish hospital. Indian J Clin Biochem 22, 52–56 (2007). https://doi.org/10.1007/BF02912881
Issue Date:
DOI: https://doi.org/10.1007/BF02912881